Over the last 30 years, concomitant with successful transnational disease control programs
across Latin America, Chagas disease has expanded from a neglected, endemic parasitic …

Introduction: Chagas disease (CD) is one of the most neglected public health problems in
the Americas, where< 1% of the estimated 6 million people with the infection have been …

Post-infectious conditions present major health burdens but remain poorly understood. In
Chagas disease (CD), caused by Trypanosoma cruzi parasites, antiparasitic agents that …

Advocacy for better drugs and access to treatment has boosted the interest in drug discovery
and development for Chagas disease, a chronic infection caused by the genetically …

Chagas disease, or American trypanosomiasis, caused by Trypanosoma cruzi parasite
infection is endemic in Latin America and presents an increasing clinical challenge due to …

The development of treatment protocols with reduced toxicity and equivalent or improved
efficacy for Trypanosoma cruzi infection is a priority. We tested the effectiveness of …

The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public
health problem throughout Latin America. Current therapeutic options are characterised by …

CYP51 is considered one of the most ancient P450 protein families. 1 It is perhaps the only
P450 protein family whose members are spread across all biological kingdoms, although it …

Chagas disease (CD) affects at least 6 million people in 21 South American countries
besides several thousand in other nations all over the world. It is estimated that at least …

Reactivation of Chagas Disease (CD) is a global public health issue. Reactivation of
disease can affect the management of CD and its clinical outcome, adding pressure to …